EGFR and non-small cell lung carcinoma: Chemotherapeutic drugs targeting the kinase activity of EGFR, including first-generation EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib, have been shown to be clinically successful in many NSCLC patients harboring an EGFR mutation.